Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Centre Jean Perrin, Clermont-Ferrand
Residual disease after chemotherapy holds prognostic value in breast cancer
February 5th, 2006
Residual disease after neoadjuvant chemotherapy holds prognostic significance in breast cancer. "Prognostic factors are used to help clinical decision-making in selecting the appropriate treatment for individual patients. The purpose of this retrospective study was to identify one or more factors associated with overall survival (OS) and disease-free survival (DFS), in 710 patients (pts) with operable breast cancer, subjected to neoadjuvant chemotherapy followed by surgery, radiotherapy and adjuvant treatments," investigators in France reported. "At a median follow-up of 7.6 years, univariate analysis showed that pathological complete response (pCR)...
Source: Women's Health Law Weekly (2006-02-05)
|
